PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (Nasdaq:ARWR) announced today that majority owned subsidiary, Insert Therapeutics, Inc., has completed a $10 million private placement with a select group of accredited investors, including a $5 million follow-on investment by Arrowhead itself.
